Last reviewed · How we verify

Human Insulin Mix 50:50

Eli Lilly and Company · Phase 3 active Small molecule

Human Insulin Mix 50:50 is a Insulin preparation Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Human Insulin Mix 50:50 replaces deficient endogenous insulin by binding to insulin receptors on target cells to promote glucose uptake and utilization.

Human Insulin Mix 50:50 replaces deficient endogenous insulin by binding to insulin receptors on target cells to promote glucose uptake and utilization. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameHuman Insulin Mix 50:50
SponsorEli Lilly and Company
Drug classInsulin preparation
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

This is a fixed combination of 50% human insulin NPH (intermediate-acting) and 50% human insulin regular (rapid-acting). The rapid-acting component provides immediate postprandial glucose control, while the intermediate-acting component provides basal coverage. Together, they mimic physiologic insulin secretion patterns by activating insulin receptors on muscle, adipose, and hepatic cells to facilitate glucose transport and metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Human Insulin Mix 50:50

What is Human Insulin Mix 50:50?

Human Insulin Mix 50:50 is a Insulin preparation drug developed by Eli Lilly and Company, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does Human Insulin Mix 50:50 work?

Human Insulin Mix 50:50 replaces deficient endogenous insulin by binding to insulin receptors on target cells to promote glucose uptake and utilization.

What is Human Insulin Mix 50:50 used for?

Human Insulin Mix 50:50 is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes Human Insulin Mix 50:50?

Human Insulin Mix 50:50 is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

What drug class is Human Insulin Mix 50:50 in?

Human Insulin Mix 50:50 belongs to the Insulin preparation class. See all Insulin preparation drugs at /class/insulin-preparation.

What development phase is Human Insulin Mix 50:50 in?

Human Insulin Mix 50:50 is in Phase 3.

What are the side effects of Human Insulin Mix 50:50?

Common side effects of Human Insulin Mix 50:50 include Hypoglycemia, Injection site reactions, Weight gain, Lipodystrophy.

What does Human Insulin Mix 50:50 target?

Human Insulin Mix 50:50 targets Insulin receptor and is a Insulin preparation.

Related